Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-1553 + cetuximab
- Development stage
- Phase 2
- Lead developer
- InventisBio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
D-1553 + cetuximab is a combination therapy for advanced or metastatic solid tumors with a KRAS G12C mutation, particularly in colorectal cancer (CRC). **D-1553 (garsorasib)** is a potent, selective, oral small molecule inhibitor targeting the KRAS G12C mutant protein. By inhibiting KRAS G12C, it disrupts oncogenic signaling through the RAS–MEK and PI3K–AKT pathways, suppressing tumor growth. **Cetuximab** is an anti-EGFR monoclonal antibody that blocks epidermal growth factor receptor signaling, frequently used in CRC. This combination is under clinical evaluation for patients who have failed standard regimens, especially those with locally advanced/metastatic CRC with KRAS G12C mutations, and has recently received Breakthrough Therapy Designation in China for this indication[2][1][3].
- Brand names
- garsorasib
- Other names
- D-1553 + cetuximab
02
Targets
EGFR (Epidermal growth factor receptor)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on D-1553 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D-1553 + cetuximab.